Skip to navigation

Bladder Cancer

Indications: Bladder Cancer
Drug Candidate: Mocetinostat
Driver Mutations: CREBBP, EP300

Mirati Therapeutics is enrolling a Phase 2 study evaluating the effects of mocetinostat as a treatment for patients with previously treated, locally advanced, unresectable or metastatic urothelial bladder cancer whose tumors carry genetic alterations of CREBBP and EP300. Participating trial sites will analyze the genetic sequence of the tumors of eligible patients to determine if those mutations are present before patients enroll in the clinical trial.

Find an Active Trial

Other Trials